Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
Recruiting
Optical coherence tomography guided laser treatment of basal cell carcinoma
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/03/2025
Locations: UCI Health Gottschalk Medical Plaza, Irvine, California
Conditions: Basal Cell Carcinoma, Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Expressive Writing for the Management of Stress in Cancer Survivors
Recruiting
This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Survey of Current Interventional and Diagnostic Imaging Residents After Participation in Endovascular Simulator Training
Recruiting
This study looks at the comfort of interventional and diagnostic imaging residents in performing simulated endovascular procedures after completing training on the Mentice endovascular simulator device. Implementation of a training curriculum with radiology residents interested in interventional radiology will help facilitate hands-on training in a low-risk environment and allow for safer future patient encounters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Malignant Vascular Neoplasm
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Recruiting
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/03/2025
Locations: Octapharma Research Site, Birmingham, Alabama +5 locations
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Recruiting
This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a fewer number of days than tradition radiation therapy courses for Merkel cell carcinoma. This may be less suppressive of the immune response to tumors and should be helpful for patient convenience.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Merkel Cell Carcinoma
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Recruiting
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
06/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Recruiting
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab. The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and ecu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The Oncology Institute of Hope & Innovation, Whittier, California +62 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: AZ Integrated Neuro and Spine, Phoenix, Arizona +243 locations
Conditions: Relapsing Multiple Sclerosis
REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19
Recruiting
Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +4 locations
Conditions: COVID-19, Critical Illness, ICU Acquired Weakness, PICS, Cardiorespiratory Fitness
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Recruiting
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective will be to evaluate genomic biomarkers associated with parasympathetic stimulation in pancreatic cancer, and the ability to reduce tumor growth rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreas Cancer
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Recruiting
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.\ Objective: To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with PDS01ADC is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
Recruiting
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Mayo Clinic, Rochester, Minnesota +3 locations
Conditions: Cardiogenic Shock, Mitral Regurgitation